News

Fierce Pharma4d
Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...
Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Devdiscourse5d
Eli Lilly Intensifies Legal Battle Over Tirzepatide Knockoff Sales
Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...
Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Zacks.com on MSN2h
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...
Pharmaceutical Technology on MSN5d
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...